135 related articles for article (PubMed ID: 908013)
1. Survival and cure of leukemic mice after circadian optimization of treatment with cyclophosphamide and 1-beta-D-arabinofuranosylcytosine.
Scheving LE; Burns ER; Pauly JE; Halberg F; Haus E
Cancer Res; 1977 Oct; 37(10):3648-55. PubMed ID: 908013
[TBL] [Abstract][Full Text] [Related]
2. Combined chronochemotherapy of L1210 leukemic mice using 1-beta-D-arabinofuranosylcytosine, cyclophosphamide, vincristine, methylprednisolone and cis-diamminedichloroplatinum.
Scheving LE; Burns ER; Halberg F; Pauly JE
Chronobiologia; 1980; 7(1):33-40. PubMed ID: 7192203
[TBL] [Abstract][Full Text] [Related]
3. Circadian optimization of the treatment of L1210 leukemia with 1-beta-D-arabinofuranosylcytosine, cyclophosphamide, vincristine and methylprednisolone.
Burns ER; Scheving LE
Chronobiologia; 1980; 7(1):41-51. PubMed ID: 7438892
[No Abstract] [Full Text] [Related]
4. Close reproduction by different laboratories of characteristics of circadian rhythm in 1-beta-D-arabinofuranosylcytosine tolerance by mice.
Scheving LE; Haus E; Kühl JF; Pauly JE; Halberg F; Cardoso S
Cancer Res; 1976 Mar; 36(3):1133-7. PubMed ID: 1253172
[TBL] [Abstract][Full Text] [Related]
5. Development of a cell kinetic approach to curative therapy of acute myelocytic leukemia in remission using the cell cycle-specific drug 1-beta-D-arabinofuranosylcytosine in a rat model.
Vaughan WP; Burke PJ
Cancer Res; 1983 May; 43(5):2005-9. PubMed ID: 6572561
[TBL] [Abstract][Full Text] [Related]
6. Adriamycin and cyclophosphamide in combination chemotherapy of L1210 leukemia.
Avery TL; Roberts D
Cancer Res; 1977 Mar; 37(3):678-83. PubMed ID: 837368
[TBL] [Abstract][Full Text] [Related]
7. Chronochemotherapy: L 1210 leukemia and beyond.
Halberg F; Nelson W; Cornélissen G; Haus E; Scheving LE; Good RA
Chronobiologia; 1979; 6(3):203-11. PubMed ID: 520097
[TBL] [Abstract][Full Text] [Related]
8. Chronochemotherapy of L1210 leukemic mice with cytosine arabinoside or cyclophosphamide.
Rose WC; Trader MW; Laster WR; Schabel FM
Cancer Treat Rep; 1978 Sep; 62(9):1337-49. PubMed ID: 688277
[No Abstract] [Full Text] [Related]
9. Single versus combination chemotherapy of L1210 leukemia.
Koza I; Balázová E; Ujházy V
Neoplasma; 1980; 27(6):691-6. PubMed ID: 7254424
[TBL] [Abstract][Full Text] [Related]
10. Schedule-dependent synergy and antagonism between high-dose 1-beta-D-arabinofuranosylcytosine and asparaginase in the L5178Y murine leukemia.
Schwartz SA; Morgenstern B; Capizzi RL
Cancer Res; 1982 Jun; 42(6):2191-7. PubMed ID: 7074600
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy of mouse leukemia L1210 by 1-beta-D-arabinofuranosylcytosine and 6-[(4-nitrobenzyl)thio]-9-beta-D-ribofuranosylpurine.
Cass CE; Muzik H; Paterson AR
Cancer Res; 1975 May; 35(5):1187-93. PubMed ID: 1120308
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugated with polyglutamic acid and its derivative.
Kato Y; Saito M; Fukushima H; Takeda Y; Hara T
Cancer Res; 1984 Jan; 44(1):25-30. PubMed ID: 6197162
[TBL] [Abstract][Full Text] [Related]
13. Stealth liposomes: an improved sustained release system for 1-beta-D-arabinofuranosylcytosine.
Allen TM; Mehra T; Hansen C; Chin YC
Cancer Res; 1992 May; 52(9):2431-9. PubMed ID: 1568213
[TBL] [Abstract][Full Text] [Related]
14. Circadian bioperiodic response of mice bearing advanced L1210 leukemia to combination therapy with adriamycin and cyclophosphamide.
Scheving LE; Burns ER; Pauly JE; Halberg F
Cancer Res; 1980 May; 40(5):1511-5. PubMed ID: 7370988
[No Abstract] [Full Text] [Related]
15. Effects of 2'-deoxycoformycin, 9-beta-D-arabinofuranosyladenine 5'-phosphate, and 1-beta-D-arabinofuranosylcytosine triple combination therapy on intracerebral leukemia 1210.
Caron N; Lee SH; Kimball AP
Cancer Res; 1977 Sep; 37(9):3274-9. PubMed ID: 884674
[TBL] [Abstract][Full Text] [Related]
16. Effect of the interval between high dose 1-beta-D-arabinofuranosylcytosine injections on leukemic cell load, intestinal toxicity, and normal hematopoietic stem cells in a rat model for acute myelogenous leukemia.
Colly LP; Peters WG; Willemze R
Cancer Res; 1986 Aug; 46(8):3825-7. PubMed ID: 3460691
[TBL] [Abstract][Full Text] [Related]
17. Basis of observed resistance of L1210 leukemia in mice: methotrexate, 6-thioguanine, 6-methylmercaptopurine riboside, 6-mercaptopurine, 5-fluorouracil, and 1-beta-D-arabinofuranosylcytosine administered in different combinations.
Kim K; Blechman WJ; Riddle VG; Pardee AB
Cancer Res; 1981 Nov; 41(11 Pt 1):4529-34. PubMed ID: 7198006
[TBL] [Abstract][Full Text] [Related]
18. Production of N4-succinyl-1-beta-D-arabinofuranosylcytosine, a novel metabolite of N4-behenoyl-1-beta-D-arabinofuranosylcytosine, in mice and its biological significance.
Oh-ishi J; Kataoka T; Tsukagoshi S; Sakurai Y; Shibukawa M; Kobayashi H
Cancer Res; 1981 Jun; 41(6):2501-6. PubMed ID: 7237444
[TBL] [Abstract][Full Text] [Related]
19. [Chronobiological aspects of experimental leukemia].
Ratte J; Haus E; Halberg F; Kühl JF; Shiotsuka R; Najarian JS
Union Med Can; 1974 Jul; 103(7):1201-7. PubMed ID: 4842174
[No Abstract] [Full Text] [Related]
20. Therapy of central nervous system leukemia in mice by liposome-entrapped 1-beta-D-arabinofuranosylcytosine.
Hong F; Mayhew E
Cancer Res; 1989 Sep; 49(18):5097-102. PubMed ID: 2766280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]